Updates are available Correction dated 2019-12-21
Click to view Correction: https://0-doi-org.brum.beds.ac.uk/10.1186/s12883-019-1568-z
-
Authors
Brown, Brandon
Weiss, Jamie L.
Kolodny, Scott
Meng, Xiangyi
Williams, Ian M.
Osborne, John A.
-
Funding
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation (-)
- License Information
-
More Information
Article History
Received: 31 January 2019
Accepted: 21 October 2019
First Online: 15 November 2019
Change Date: 21 December 2019
Change Type: Correction
Change Details: Following publication of the original article [1], the authors reported a mistake regarding the year found in the paragraph of the Background section.
Ethics approval and consent to participate
: IRB exemption was granted by Advarra IRB (Advarra, Columbia, MD) based on the study meeting the criteria: “Information, including information about the biospecimens, will be recorded in such a manner that the identity of the human subjects cannot readily be ascertained directly or through identifiers linked to the subjects, the investigator will not contact subjects, and the investigator will not reidentify subjects.”
: Not applicable.
: BB, JLW, SK, and XM are employees of Novartis Pharmaceuticals Corporation. IMW is an employee of Oxford PharmaGenesis. JAO has received honoraria for educational programs that he has provided on behalf of Novartis, as well as consultation fees for Gilenya@Home. In addition, he is Medical Director of the Gilenya@Home program.
